ArticleBMC cancer2025
Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Beta-blocker use and survival outcomes in colorectal cancer patients: A systematic review and meta-analysis.The Journal of international medical research · 2025Pooled it
- Epidemiology of liver cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014-2023.PloS one · 2025Article
- Application of immunotherapy in advanced non-small cell lung cancer with hypertension: a multicenter retrospective analysis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArterial hypertension is one of the most frequent comorbidities in patients with cancer. Studies have indicated that drugs used to control hypertension may alter cancer patient survival; however, epidemiological findings for their impact on cancer survival remain inconsistent. The aim of this study was to examine the effect of the consumption of antihypertensive (AH) medication on the risk of death in cancer patients.
methodsThe association between 1-year postdiagnostic AH medication intake and the risk of death was examined in a population-based cohort of cancer patients including colorectal (N = 1104), lung (N = 344), melanoma (N = 334), corpus uteri (N = 832) and kidney cancer (N = 714), diagnosed between 2013 and 2015, and identified from the Lithuanian Cancer Registry. Multivariate Cox proportional hazards models were used to estimate hazard ratios (HRs), and corresponding 95% confidence intervals (95% CI) to assess associations between AH medications and cancer-specific and overall mortality.
resultsWe found a statistically significant decrease in mortality among colorectal cancer patients who were users of angiotensin receptor blockers (ARBs) (HR: 0.68, 95% CI: 0.47-0.98) or angiotensin converting enzyme inhibitors (ACEIs) (HR: 0.69, 95% CI: 0.52-0.91). A higher usage of ARBs and ACEIs was related to further improved colorectal cancer survival (HR 0.62, 95% CI: 0.39-1.00 and HR 0.60, 95% CI: 0.42-0.86, respectively). The subgroup analyses also demonstrated significantly better cancer specific survival in ARB users and ACEI users versus non-users in colorectal cancer patients with adenocarcinoma, surgery treatment, chemotherapy treatment and ARB or ACEI use before diagnosis. The results suggest a lower mortality among colorectal cancer patients with a higher usage of diuretics. Increased cancer-specific mortality was observed among corpus uteri cancer patients using ARBs and among melanoma patients using beta blockers (BBs); however, there was no evidence of consistent statistically significant associations in subgroup analyses.
conclusionThis study supports a link between ARB and ACEI use and increased survival among colorectal cancer patients. Further research is needed to provide a detailed evaluation of the effects of AH medications on cancer survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.